Eli Lilly (LLY) executive says commercial access for Foundayo has been confirmed at two of the three largest US PBMs, effective mid-May
Context
Eli Lilly securing commercial access for Foundayo with two of the largest US PBMs is a significant win that may enhance market penetration and revenue potential for the drug. This development not only validates their product's positioning but also suggests a positive trajectory for Eli Lilly's growth, which could influence investor sentiment and draw analyst attention. Keep an eye on how this affects sector peers and overall market momentum in the pharmaceuticals space.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#ELI LILLY & CO#LLY.US#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#US EQUITIES